Sign In
Buy SPEX
$0.428
+0 (+0%)
At Close: Aug 17, 2022
Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis' Fabhalta and Alexion/AstraZeneca's Voydeya. Spherix Global Insig
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
03:43pm, Monday, 17'th Jun 2024
Leigh Anne Siino joins executive team to accelerate company's revenue growth. Leigh Anne Siino joins executive team to accelerate company's revenue growth.
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
04:00am, Monday, 10'th Jun 2024
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth. Spherix diversifies portfolio with st
Spherix Global Insights Partners With Content Catalyst to Launch Best-in-class Client Portal
11:00am, Wednesday, 09'th Aug 2023
CAMBRIDGE, England--(BUSINESS WIRE)-- #analyst--Spherix Global Insights partners with specialist technology provider Content Catalyst to deploy their advanced portal for clients to interact with Spher
EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable shar
EXTON, Pa., Nov. 9, 2020 /PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologis
101 Stocks Moving In Monday's Mid-Day Session
04:00pm, Monday, 09'th Mar 2020
Gainers
Spherix Incorporated (NASDAQ: SPEX) shares jumped 139% to $3.92 after jumping 131% on Friday.
AIM ImmunoTech Inc. (NYSE: AIM) shares jumped 63.1% to $3.43 amid the...
